Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 study

被引：0
|
作者：
Andrews, J. M. [1 ]
D'Haens, G. [2 ]
Kobayashi, T. [3 ]
Morris, N. [4 ]
Lissoos, T. [4 ]
Hoover, A. [4 ]
Li, X. [4 ]
Arora, V. [4 ]
Milch, C. [4 ]
Sandborn, W. J. [5 ]
Sands, B. E. [6 ]
机构：
[1] Univ Adelaide, Royal Adelaide Hosp, Adelaide, SA, Australia
[2] Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[3] Kitasato Univ, Kitasato Inst Hosp, Ctr Adv IBD Res & Treatment, Tokyo, Japan
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Univ Calif San Diego, La Jolla, CA 92093 USA
[6] Icahn Sch Med Mt Sinai, Div Gastroenterol, New York, NY 10029 USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2022年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
114
引用
收藏
页码：132 / 133
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I028 - I029
  • [2] EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
    D'Haens, Geert
    Kobayashi, Taku
    Morris, Nathan
    Lissoos, Trevor
    Hoover, Amy
    Li, Xingyuan
    Arora, Vipin
    Milch, Catherine
    Sandborn, William J.
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S214 - S214
  • [3] EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: PHASE 3 LUCENT-1 STUDY RESULTS
    D'Haens, Geert
    Kobayashi, Taku
    Morris, Nathan
    Lissoos, Trevor
    Hoover, Amy
    Li, Xingyuan
    Arora, Vipin
    Milch, Catherine
    Sandborn, William J.
    Sands, Bruce E.
    Irving, Peter
    GUT, 2022, 71 : A16 - A17
  • [4] Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial
    Danese, Silvio
    Dignass, Axel
    Matsuoka, Katsuyoshi
    Ferrante, Marc
    Long, Millie
    Redondo, Isabel
    Gibble, Theresa Hunter
    Moses, Richard
    Morris, Nathan
    Li, Xingyuan
    Milch, Catherine
    Abreu, Maria T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S535 - S535
  • [5] EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
    Dubinsky, Marla C.
    Irving, Peter M.
    Li, Xingyuan
    Howaldt, Stefanie
    Pokrotnieks, Juris
    Krueger, Kathryn A.
    Laskowski, Janelle
    Lissoos, Trevor
    Milata, Joe
    Morris, Nathan
    Arora, Vipin
    Milch, Catherine
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S1393 - S1394
  • [6] Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies
    Kobayashi, Taku
    Matsuoka, Katsuyoshi
    Watanabe, Mamoru
    Hisamatsu, Tadakazu
    Hirai, Fumihito
    Milata, Joe
    Li, Xingyuan
    Morris, Nathan
    Arora, Vipin
    Ishizuka, Tomoko
    Matsuo, Koji
    Satoi, Yoichi
    Milch, Catherine
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2024, 22 (02) : 172 - 185
  • [7] Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study
    Begun, J.
    Dubinsky, M. C.
    Irving, P. M.
    Li, X.
    Howaldt, S.
    Pokrotnieks, J.
    Krueger, K.
    Laskowski, J.
    Lissoos, T.
    Milata, J.
    Morris, N.
    Arora, V.
    Milch, C.
    Sands, B. E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 133 - 133
  • [8] Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study
    Schreiber, S. W.
    Clemow, D. B.
    Keohane, A.
    Zhu, B.
    Ritter, T.
    Regueiro, M.
    Hudesman, D.
    Chen, Y. F.
    Owen, C.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1975 - I1976
  • [9] Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
    Sands, Bruce E.
    Feagan, Brian G.
    Gibble, Theresa Hunter
    Traxler, Kristina A.
    Morris, Nathan
    Eastman, William J.
    Schreiber, Stefan
    Jairath, Vipul
    Long, Millie D.
    Armuzzi, Alessandro
    CROHNS & COLITIS 360, 2023, 5 (04)
  • [10] Mirikizumab Improves Mental and Physical Health Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
    Sands, Bruce E.
    Feagan, Brian G.
    Gibble, Theresa Hunter
    Traxler, Kristina A.
    Morris, Nathan
    Li, Xingyuan
    Eastman, William J.
    Schreiber, Stefan
    Jairath, Vipul
    Armuzzi, Alessandro
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S528 - S529
12345